In vivo pharmacokinetic and pharmacodynamic study of co-spray-dried inhalable pirfenidone microparticles in rats

Pirfenidone (PRF) is the first FDA-approved API in the treatment of idiopathic pulmonary fibrosis (IPF). However, PRF induces serious side effects, such as photophobia and gastrointestinal disorder. PRF inhalation can be expected with a lower effective dose and reduced side effects. In this study, P...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Ji-Hyun, Yang, Min-Seok, Kim, Dong-Wook, Park, Chun-Woong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704105/
https://www.ncbi.nlm.nih.gov/pubmed/36415157
http://dx.doi.org/10.1080/10717544.2022.2149899

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9704105/
https://www.ncbi.nlm.nih.gov/pubmed/36415157
http://dx.doi.org/10.1080/10717544.2022.2149899

Ejemplares similares